Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type -1

Evaluation of Decongestion Guided By VExUS Score Or Lung Ultrasound For Renal Recovery In Patients With Cardiorenal Syndrome Type-1 : a Randomized Controlled Trial

Status

Enrolling by invitation

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06786728

Enrollment

146

Registered

2025-01-22

Start date

2024-08-10

Completion date

2025-08-31

Last updated

2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiorenal Syndrome Type 1

Brief summary

the goal of this observational study is to evaluate the role of VEXUS score and lung ultrasound to guide decongestive therapy in patients with cardiorenal syndrome type -1. the main question it aims to answer is: Can the VEXUS score and lung ultrasound guide the efffect of decongestive therapy on KFR and decongestion metrics in patients with CRS-1 compared to standard assesment ?

Interventions

DRUGfrusemide

in this group we use vexus score to asses decongestion in comparison to lung ultrasound in other group

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* • Patients of both genders aged 18-65 years old. * Patients with CRS1 criteria (worsening of renal function due to acute heart failure manifested by : ( Dyspnea , orthopnea ,hypoxia , congested neck veins , oliguria and congestion in imaging.) * Patients with Modified lung ultrasound score(LUSS) more than 15.

Exclusion criteria

* • Refusal to participate. * Patients with renal transplantation. * Unknowing baseline creatinine. * Patients with a life-threatening indication of RRT (defined as intractable hyperkalemia, acidosis, uremic symptoms) at enrollment, * RRT before recruitment, * known prehospitalization advanced chronic kidney disease (defined by an estimated GFR \<30 mL/min/1.73 m2 or chronic RRT), * use of extracorporeal membrane oxygenation (ECMO), * diagnosis of hepatic cirrhosis or other condition with portal hypertension * Or postrenal causes of AKI

Design outcomes

Primary

Measure	Time frame	Description
assesment of KFR using the KDIGO AKI staging improvement	1 week	stage1:serum creatinine increase 1,5 - 2 folds serum creatinine increase 2 - 3 folds serum creatinine increase more than 3 folds

Secondary

Measure	Time frame	Description
VEXUS score	48 hours	grade 1 : no congestion grade 2:mild congestion grade 3 moderate congestion grade 4 : severe congestion

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026